Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease

被引:89
作者
Magistroni, R
He, N
Wang, KR
Andrew, R
Johnson, A
Gabow, P
Dicks, E
Parfrey, P
Torra, R
San-Millan, JL
Coto, E
Van Dijk, M
Breuning, M
Peters, D
Bogdanova, N
Ligabue, G
Albertazzi, A
Hateboer, N
Demetriou, K
Pierides, A
Deltas, C
St George-Hyslop, P
Ravine, D
Pei, Y
机构
[1] Univ Hlth Network, Div Genom Med, Toronto, ON M5G 2C4, Canada
[2] Univ Colorado, Hlth Sci Ctr, Div Renal, Denver, CO USA
[3] Mem Univ Newfoundland, Div Nephrol, St John, NF, Canada
[4] Fundacio Puigvert, Div Nephrol, Barcelona, Spain
[5] Hosp Ramon & Cajal, Unidad Genet Mol, E-28034 Madrid, Spain
[6] Univ Oviedo, Hosp Cent Asturias, Inst Reina Sofia Invest Nephrol, E-33080 Oviedo, Spain
[7] Acad Hosp Leiden, Leiden, Netherlands
[8] Leiden Univ, Afdeling Anthropogenet, Leiden, Netherlands
[9] Univ Munster, Inst Human Genet, D-4400 Munster, Germany
[10] Univ Modena & Reggio Emilia, Div Nephrol, Modena, Italy
[11] Univ Wales Hosp, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales
[12] Nicosia Gen Hosp, Dept Nephrol, Nicosia, Cyprus
[13] Univ Cyprus, Dept Sci Biol, Nicosia, Cyprus
[14] Cyprus Inst Neurol & Genet, Dept Mol Genet, Nicosia, Cyprus
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷 / 05期
关键词
D O I
10.1097/01.ASN.0000061774.90975.25
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Autosomal dominant polycystic kidney disease (ADPKD) is a common Mendelian disorder that affects approximately 1 in 1000 live births. Mutations of two genes, PKD1 and PKD2, account for the disease in approximately 80 to 85% and 10 to 15% of the cases, respectively. Significant interfamilial and intrafamilial renal disease variability in ADPKD has been well documented. Locus heterogeneity is a major determinant for interfamilial disease variability (i.e., patients from PKD1-linked families have a significantly earlier onset of ESRD compared with patients from PKD2-linked families). More recently, two studies have suggested that allelic heterogeneity might influence renal disease severity. The current study examined the genotype-renal function correlation in 461 affected individuals from 71 ADPKD families with known PKD2 mutations. Fifty different mutations were identified in these families, spanning between exon 1 and 14 of PKD2. Most (94%) of these mutations were predicted to be inactivating. The renal outcomes of these patients, including the age of onset of end-stage renal disease (ESRD) and chronic renal failure (CRF; defined as creatinine clearance less than or equal to 50 ml/min, calculated using the Cockroft and Gault formula), were analyzed. Of all the affected individuals clinically assessed, 117 (25.4%) had ESRD, 47 (10.2%) died without ESRD, 65 (14.0%) had CRF, and 232 (50.3%) had neither CRF nor ESRD at the last follow-up. Female patients, compared with male patients, had a later mean age of onset of ESRD (76.0 [95% CI, 73.8 to 78.1] versus 68.1 [95% Cl, 66.0 to 70.2] yr) and CRF (72.5 [95% Cl, 70.1 to 74.9] versus 63.7 [95% CI, 61.4 to 66.0] yr). Linear regression and renal survival analyses revealed that the location of PKD2 mutations did not influence the age of onset of ESRD. However, patients with splice site mutations appeared to have milder renal disease compared with patients with other mutation types (P < 0.04 by log rank test; adjusted for the gender effect). Considerable renal disease variability was also found among affected individuals with the same PKD2 mutations. This variability can confound the determination of allelic effects and supports the notion that additional genetic and/or environmental factors may modulate the renal disease severity in ADPKD.
引用
收藏
页码:1164 / 1174
页数:11
相关论文
共 49 条
[1]   Mutations in autosomal dominant polycystic kidney disease 2 gene: Reduced expression of PKD2 protein in lymphoblastoid cells [J].
Aguiari, G ;
Manzati, E ;
Penolazzi, L ;
Micheletti, F ;
Augello, G ;
Vitali, ED ;
Cappelli, G ;
Cai, YQ ;
Reynolds, D ;
Somlo, S ;
Piva, R ;
del Senno, L .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (05) :880-885
[2]   Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease [J].
Baboolal, K ;
Ravine, D ;
Daniels, J ;
Williams, N ;
Holmans, P ;
Coles, GA ;
Williams, JD .
KIDNEY INTERNATIONAL, 1997, 52 (03) :607-613
[3]   Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease [J].
Carrasquillo, MM ;
McCallion, AS ;
Puffenberger, EG ;
Kashuk, CS ;
Nouri, N ;
Chakravarti, A .
NATURE GENETICS, 2002, 32 (02) :237-244
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   EVIDENCE FOR A 3RD GENETIC-LOCUS FOR AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
DAOUST, MC ;
REYNOLDS, DM ;
BICHET, DG ;
SOMLO, S .
GENOMICS, 1995, 25 (03) :733-736
[7]   Mutations of the human polycystic kidney disease 2 (PKD2) gene [J].
Deltas, CC .
HUMAN MUTATION, 2001, 18 (01) :13-24
[8]   Autosomal dominant polycystic kidney disease - type 2. Ultrasound, genetic and clinical correlations [J].
Demetriou, K ;
Tziakouri, C ;
Anninou, K ;
Eleftheriou, A ;
Koptides, M ;
Nicolaou, A ;
Deltas, CC ;
Pierides, A .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (02) :205-211
[9]   Modifier genes convert "simple" Mendelian disorders to complex traits [J].
Dipple, KM ;
McCabe, ERB .
MOLECULAR GENETICS AND METABOLISM, 2000, 71 (1-2) :43-50
[10]   AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :332-342